Commercially available GSK inhibitors of PERK (GSK2656157, GSK2606414) significantly decreased neurodegeneration in animal models of PD, prion disease and traumatic brain injury (TBI) [155,284,285]. This evidence concerns the gene EIF2AK3 and Parkinson disease.